University of California, San Francisco at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
University of California, San Francisco takes part in 10 sessions at CTAD 2026 in Boston. Its program spans imaging, blood biomarkers and digital assessment, including the posdinemab anti-tau trial and early-onset Alzheimer's disease. Its work covers a voice-based Clinical Dementia Rating, multimodal biomarker integration and real-world outcomes of anti-amyloid antibodies.
| Organization | CTAD 2026 Attendance |
|---|---|
University of California, San Francisco San Francisco, California | |
Its Memory and Aging Center studies Alzheimer's and frontotemporal dementia, including early-onset Alzheimer's in the LEADS study. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Session Mon Nov 16 3:15pm–3:25pm Talk Tue Nov 17 8:30am–9:10am Talk Tue Nov 17 11:05am–11:45am Session Tue Nov 17 11:05am–11:45am Talk Wed Nov 18 9:30am–9:55am Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Talk Thu Nov 19 9:40am |
Instantly find 20 buyers from University of California, San Francisco
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction